Navigation Links
Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
Date:12/15/2011

THOUSAND OAKS, Calif., Dec. 15, 2011 /PRNewswire/ -- Kevin W. Sharer, chairman and chief executive officer of Amgen (NASDAQ: AMGN) since 2000, has announced his plan to retire from the Company at the end of 2012, following 20 years of service to Amgen.  To facilitate an orderly transition process, Sharer will step down as CEO effective May 23, 2012, and remain as chairman of the Company's Board of Directors until December 31, 2012, at which time he will retire from the Board and from the Company.  Robert Bradway, currently president and chief operating officer, will become CEO on May 23, 2012.  It is the intention of the Board of Directors to elect Bradway chairman of the Board when Sharer retires from that position at the end of 2012.  The Board will also elect a lead independent director at that time.

On behalf of the Board of Directors, Vance Coffman, chairman of the Board's governance and nominating committee said, "The Board thanks Kevin Sharer for his service in leading Amgen over the past decade.  During that time Amgen grew significantly in every dimension and is well positioned for the future.  Amgen's core mission to serve patients remains our bedrock.  The Board is excited to have a talented executive in Bob Bradway as the fourth CEO in our Company's history."  

"Today Amgen announces its next generation of leaders as we pass the reins to Bob Bradway and Sean Harper," said Kevin Sharer.  "Bob and Sean have demonstrated sound judgment, delivered consistently excellent operating results and provided strong leadership in a variety of challenging roles.  Amgen will be in good hands.  I would particularly like to thank Roger Perlmutter for his eleven years of service.  He has been an outstanding head of research and development, and his accomplishments have benefited millions of patients.  In the months ahead, we will focus on making the transition to Bob and Sean seamless."

Sharer, 63, joined Amgen in 1992 and served as president until 2000 when he was named chairman and CEO.  Under his tenure Amgen grew from $3.6B in revenue with a presence in 17 countries to a company today with revenues approaching $16B and operations in 55 countries.

Bob Bradway, 48, joined Amgen in 2006 as a vice president in operations.  He was appointed CFO in 2007, and was named president and chief operating officer in 2010.  Prior to joining Amgen, Bradway worked for 19 years with Morgan Stanley.  Bradway holds a BA in Biology from Amherst College and an MBA from Harvard University.

Roger Perlmutter, 59, will retire as executive vice president of research and development effective February 12, 2012.  Dr. Perlmutter will then work with Amgen as a consultant to aid in the transition until February, 2013.  Dr. Perlmutter joined Amgen in 2000, and during his tenure Amgen has gained the approval for many new drugs, including Aranesp®, Neulasta®, Vectibix®, Nplate®, Sensipar® and Amgen's newest drugs, Prolia® and Xgeva®.

Sean Harper, 49, will assume his new role on February 13, 2012, reporting to Bob Bradway.  Dr. Harper will be responsible for Amgen's global research and development functions.  Dr. Harper joined Amgen in 2002, and has held leadership roles in early development, medical sciences and global regulatory and safety.  His current role is senior vice president, global development and he serves as chief medical officer for Amgen.   Prior to joining Amgen, Dr. Harper worked for 6 years at Merck Research Laboratories.  He attended medical school at UCSF, was board certified in internal medicine and gastroenterology after training at the Massachusetts General Hospital and was a postdoctoral fellow at the Massachusetts Institute of Technology.

 

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com.  Follow us on www.twitter.com/amgen.

 

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

 


 

 

 


'/>"/>
SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Verenium Appoints Kevin Bracken Vice President of Manufacturing
2. Kevin Kruse Named Executive Director of the Society of Pharmaceutical and Biotech Trainers
3. Kevin Garrity Named President of HollisterStier Allergy
4. SeraCare Announces the Election of Joseph Nemmers and Kevin Hrusovsky to the Board of Directors
5. Amgen Announces Webcast of 2008 Third Quarter Financial Results
6. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
7. Call for Applications: The Amgen Award for Science Teaching Excellence
8. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
9. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
10. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
11. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of the ... brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing ... to its list of well-respected retailers. This list includes such fine stores as ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
Breaking Biology Technology:
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
Breaking Biology News(10 mins):